ArticleJournal of hepatocellular carcinoma2025
Efficacy and Safety Analysis of Transarterial Chemoembolization Combined with Sintilimab Plus Bevacizumab Biosimilar in the Treatment of Unresectable Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD-1 Inhibitor Plus TKIs in Combination of TACE for uHCC.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab.Frontiers in oncology · 2026Article
- Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab in hepatocellular carcinoma.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization (TACE) remains a cornerstone for unresectable hepatocellular carcinoma (uHCC) but is limited by tumor progression. Combining TACE with systemic therapies may enhance efficacy. Notably, sintilimab combined with bevacizumab biosimilar has shown synergistic effects in tumor control and has been incorporated into the first-line treatment regimen in China. This study evaluates the therapeutic efficacy and safety of TACE combined with sintilimab and bevacizumab biosimilar in patients with uHCC. Methods: This retrospective cohort study analyzed 76 uHCC patients who received TACE plus sintilimab-bevacizumab biosimilar at the First Affiliated Hospital of Guilin Medical University between September 2020 and March 2024, with follow-up continuing until March 31, 2025. The primary outcomes, overall survival (OS) and progression-free survival (PFS), were evaluated through Kaplan-Meier survival analysis. Independent risk factors for OS and PFS were evaluated using both univariate and multivariate analyses. Secondary outcomes comprised objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (tr-AEs). Results: The study cohort comprised 76 patients meeting predefined eligibility criteria, achieving median OS of 23.2 months and median PFS of 14.5 months. Tumor response was assessed per mRECIST criteria, demonstrating an ORR of 59.2% and DCR of 81.6%. Multivariable analysis confirmed the modified albumin-bilirubin (mALBI) grade 3, alpha-fetoprotein (AFP) level, and macrovascular invasion as independent risk factors for OS and PFS (all P<0.05). All tr-AEs were manageable, with no fatal events reported. Conclusion: TACE combined with sintilimab and bevacizumab biosimilar demonstrated favorable efficacy and manageable safety in patients with uHCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.